智通财经APP讯，石四药集团(02005)公布，于2025年10月27日的中国第十一批全国药品集中采购招标 中，该集团共十二个产品十四个品规分别拟中标：二羟丙茶硷注射液(2ml:0.3g)、富马酸福莫特罗吸入 溶液(2ml:20µg)、马来酸氟伏沙明片(100mg 及50mg)、注射用氯诺昔康(8mg)、盐酸肾上腺素注射液 (1ml:1mg)、盐酸溴己新注射液(2ml:4mg)、复方电解质注射液(500ml)、复方电解质注射液(II)(500ml 及 1000ml)、尼可地尔片(5mg)、硫酸沙丁胺醇注射液(1ml:0.5mg)、盐酸贝尼地平片(8mg)及碳酸氢钠注射 液 (50ml:4.2g)。 ...

格隆汇10月28日丨石四药集团(02005.HK)发布公告，于2025年10月27日的中国第十一批全国药品集中采 购招标中，集团共十二个产品十四个品规分别拟中标：二羟丙茶硷注射液(2ml:0.3g)、富马酸福莫特罗 吸入溶液(2ml:20μg)、马来酸氟伏沙明片(100mg 及50mg)、注射用氯诺昔康(8mg)、盐酸肾上腺素注射液 (1ml:1mg)、盐酸溴己新注射液(2ml:4mg)、复方电解质注射液(500ml)、复方电解质注射液(II)(500ml 及 1000ml)、尼可地尔片(5mg)、硫酸沙丁胺醇注射液(1ml:0.5mg)、盐酸贝尼地平片(8mg)及碳酸氢钠注射 液 (50ml:4.2g)。 ...

本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 全國藥品集中採購擬中選結果 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 於二零二五年十月二十七日的中國第十一批全國藥品集中採購招標中，本集團共十二個產品十 四個品規分別擬中標：二羥丙茶鹼注射液(2ml:0.3g)、富馬酸福莫特羅吸入溶液(2ml:20µg)、 馬來酸氟伏沙明片(100mg 及50mg)、注射用氯諾昔康(8mg)、鹽酸腎上腺素注射液(1ml:1mg)、 鹽酸溴己新注射液(2ml:4mg)、複方電解質注射液(500ml)、複方電解質注射液(II)(500ml 及 1000ml)、尼可地爾片(5mg)、硫酸沙丁胺醇注射液(1ml:0.5mg)、鹽酸貝尼地平片(8mg)及碳酸 氫鈉注射液 (50ml:4.2g)。 承董事局命 執行董事兼公司秘書 周興揚 香港， ...

近日，石四药集团发布公告，公司以仿制4类报产的苯磺酸左氨氯地平片获批并视同过评。摩熵医药数据显示，截至目前， 该品种有超20家药企获批并过评。 截图来源：企业官网 苯磺酸左氨氯地平片是一种钙通道阻滞剂，通过选择性抑制血管平滑肌细胞膜上的钙离子内流，降低外周血管阻力，从而发 挥降压和缓解心绞痛的作用。据摩熵医药数据库显示，苯磺酸左氨氯地平片在2024年全终端医院市场的销售额超20亿元，是 全终端医院心血管系统药物销售TOP10品种。 截图来源：摩熵医药过评药品汇总数据库 从企业竞争格局分析，在2024年全终端医院市场中，苯磺酸左氨氯地平片呈现出三足鼎立的态势。其中，扬子江药业以 27.61%的市场份额傲居榜首；华北制药紧随其后，占据25.24%的市场份额，位列第二；南昌弘益药业则以16.31%的市场份额 位居第三。 截图来源：摩熵医药全终端医院销售数据库 截图来源：摩熵医药全终端医院销售数据库 截至目前，苯磺酸左氨氯地平片有石家庄四药、华北制药、扬子江药业集团等22家企业过评，其中4家药企进入第八批集 采。在仿制药布局方面，有江苏万高药业、湖南九典制药等超30家企业以仿制4类报产在审。 | 药品名称:苯磺酸左旋 ...

Summary of Key Points Core Viewpoint - On October 21, 32 Hong Kong-listed companies conducted share buybacks, totaling 14.32 million shares and an aggregate amount of HKD 58.19 million [1]. Group 1: Buyback Details - The company YunGongChang repurchased 2.10 million shares for HKD 8.22 million, with a highest price of HKD 3.980 and a lowest price of HKD 3.880, bringing its total buyback amount for the year to HKD 119 million [1][2]. - LianYiRong Technology-W repurchased 2.38 million shares for HKD 7.45 million, with a highest price of HKD 3.180 and a lowest price of HKD 3.100, totaling HKD 218 million in buybacks for the year [1][2]. - Mengniu Dairy repurchased 0.50 million shares for HKD 7.26 million, with a highest price of HKD 14.550 and a lowest price of HKD 14.460, accumulating HKD 451 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on October 21 was from YunGongChang at HKD 8.22 million, followed by LianYiRong Technology-W at HKD 7.45 million, and Mengniu Dairy also featured prominently [1][2]. - In terms of share quantity, LianYiRong Technology-W led with 2.38 million shares repurchased, followed by ShiSiYao Group and YunGongChang, each with 2.10 million shares [1][2]. Group 3: Additional Insights - KJ Pharma-B conducted its first buyback of the year, while Mengniu Dairy has made multiple buybacks totaling HKD 451 million [2]. - A detailed table of buybacks on October 21 includes various companies, their respective share counts, amounts, and price ranges, highlighting the active buyback environment in the Hong Kong market [2][3].

Group 1 - Multiple companies conducted share buybacks on October 21, 2025, with a total of 30 companies listed [1] - The largest buyback was by Cloud Factory (N23027), repurchasing 2.1 million shares for a total of 8.22 million yuan [1][2] - Other notable buybacks include Linklogis Technology (W09959) with 2.38 million shares for 7.45 million yuan and Mengniu Dairy (02319) with 500,000 shares for 7.26 million yuan [2] Group 2 - Cumulative buyback amounts for the year show Cloud Factory (N23027) has repurchased a total of 26.62 million shares, representing 5.786% of its total share capital [2] - Linklogis Technology (W09959) has repurchased 67.82 million shares, accounting for 3.174% of its total share capital [2] - Other companies with significant cumulative buybacks include Stone Four Pharmaceutical (02005) with 39.20 million shares (1.328%) and Kangchen Pharmaceutical (01681) with 6.50 million shares (7.637%) [2][3]

备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 股票名称 机构名称 性质 变动前持股 变动后持股 持股比 石四药集团(02005) 曲继广 好仓 12.15 亿股 12.17 亿股 41.22%(最新) 41.15%(前次) () 黄晓凌 好仓 11.00 万股 0股 0%(最新) 0.07%(前次) 智通财经APP获悉，石四药集团(02005)、()于2025年10月22日进行了最新股东权益披露。 ...

Major Events - Guanghe Tong (00638) has set the offer price at HKD 21.5 per share, with the public offering receiving a subscription rate of 550.99 times [1] - China Biologic Products (01177) announced the Phase III study data of Kymriah combined with Fluvestrant for the first-line treatment of advanced breast cancer will be presented at ESMO 2025 [1] - Derun Holdings (01709) plans to conduct a placement of new shares at a discount of approximately 11.34%, aiming to raise about HKD 761 million [1] - New World Development (00017) clarified media reports, stating that it has not undertaken any debt management projects regarding perpetual and other debt securities [1] - China Shenhua (01088) reported that Unit 4 of the Jiujiang Phase II project has successfully completed a 168-hour trial run [1] - Jingwei TianDi (02477) has acquired a TCSP licensed company and launched a new feature called FOPAY [1] - Rongzun International Holdings (01780) announced that its controlling shareholder intends to place up to 60% of the company's shares, reducing their stake to 15% [1] Financial Performance - Pop Mart (09992) reported a year-on-year revenue growth of 245%-250% for the third quarter [2] - China Telecom (00728) recorded a profit attributable to shareholders of RMB 30.8 billion for the first three quarters, reflecting a year-on-year increase of 5.0% [2] - Luk Fook Holdings (00590) reported that its overall retail value, retail income, and same-store sales for the second quarter exceeded the first quarter, increasing by 18%, 15%, and 10% respectively [2] - Minmetals Resources (01208) produced a total of 127,000 tons of copper in the third quarter, marking an 11% year-on-year increase [2] - Datang Power (00991) achieved a total electricity generation of approximately 2,062.41 billion kilowatt-hours in the first three quarters, up about 2.02% year-on-year [2] - Far East Horizon (03360) reported an increase in profit attributable to ordinary shareholders for the first three quarters [2] - China General Nuclear Power Corporation (01164) produced a total of 644.3 tons of natural uranium in the third quarter [2]

Core Points - The company, Shijiazhuang Pharmaceutical Group, announced a share buyback on October 21, purchasing 2.1 million shares at a price range of HKD 2.880 to HKD 2.920, totaling HKD 6.0813 million [2] - The stock closed at HKD 2.890 on the same day, reflecting a 1.05% increase, with a total trading volume of HKD 22.8912 million [2] - Year-to-date, the company has conducted 16 buybacks, acquiring a total of 45.1 million shares for a cumulative amount of HKD 133 million [2] Buyback Details - The buyback details include various dates, number of shares repurchased, highest and lowest buyback prices, and total buyback amounts, showcasing a consistent strategy to enhance shareholder value [2] - For instance, on October 14, the company repurchased 210,000 shares at a maximum price of HKD 2.940, totaling HKD 6.0908 million [2] - The highest buyback price recorded was HKD 3.440 on April 2, with a total of 280,000 shares repurchased for HKD 9.5882 million [2]

石四药集团(02005)发布公告，于2025年10月21日，该公司斥资608.13万港元回购210万股股份，每股回 购价格为2.88-2.92港元。 ...